Gridelli B, Scanlon L, Pellicci R, LaPointe R, DeWolf A, Seltman H, Diven W, Shaw B, Starzl T, Sanghvi A
Transplantation. 1986 Mar;41(3):388-91. doi: 10.1097/00007890-198603000-00021.
The influence of assay method on single dose cyclosporine (CsA) pharmacokinetics was studied in nine dogs receiving either i.v. or oral CsA. Samples were drawn from hepatic, portal, and systemic veins at various times after the dose and CsA levels were determined by radioimmunoassay (RIA) and high-performance liquid chromatography (HPLC). Blood concentration-time data were analyzed by nonlinear least-squares regression, using two-compartment models. RIA/HPLC ratios for all samples were greater than one, and did not change significantly over time. The mean RIA/HPLC ratios for samples drawn from all three veins were higher after oral than i.v. doses of the drug (P less than 0.05). Area under the concentration-time curve (AUC) was higher and systemic clearance (CIs) lower than calculated on the basis of RIA results, regardless of the route of administration. AUC calculated for CsA metabolites (RIA-HPLC) was highest in the portal vein after an oral dose of CsA. Bioavailability was 20.4% and 27.0% when estimated using HPLC and RIA data, respectively. The mean CsA metabolite index (CMI), when calculated for hepatic, portal, or systemic vein, was greater when the drug was administered orally. The mean hepatic extraction ratio (HER) of the parent drug and for CsA metabolites was approximately 23% in i.v. and p.o. studies. These results suggest that the gastrointestinal tract may play a role in the metabolism of CsA when the drug is administered orally. In addition, if CsA metabolites not measured by HPLC have either toxic or immunosuppressive properties, the RIA assay may be more useful for monitoring patients.
研究了测定方法对9只静脉注射或口服环孢素(CsA)的犬单剂量CsA药代动力学的影响。给药后不同时间从肝静脉、门静脉和体静脉采集样本,通过放射免疫分析(RIA)和高效液相色谱法(HPLC)测定CsA水平。使用二室模型通过非线性最小二乘法回归分析血药浓度-时间数据。所有样本的RIA/HPLC比值均大于1,且随时间无显著变化。口服给药后,从所有三条静脉采集的样本的平均RIA/HPLC比值高于静脉注射给药(P<0.05)。无论给药途径如何,浓度-时间曲线下面积(AUC)均高于基于RIA结果计算的值,而全身清除率(CIs)则低于基于RIA结果计算的值。口服CsA后,门静脉中CsA代谢产物的AUC(RIA-HPLC法)最高。分别使用HPLC和RIA数据估算时,生物利用度分别为20.4%和27.0%。口服给药时,肝静脉、门静脉或体静脉的平均CsA代谢产物指数(CMI)更高。在静脉注射和口服研究中,母体药物和CsA代谢产物的平均肝提取率(HER)约为23%。这些结果表明,口服CsA时胃肠道可能参与其代谢。此外,如果未通过HPLC测定的CsA代谢产物具有毒性或免疫抑制特性,则RIA测定法可能更有助于监测患者。